Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

What is the evidence that hydroxyurea improves health-related quality of life in patients with sickle cell disease? Hematology Am Soc Hematol Educ Program 2012;2012:290-1

Date

12/13/2012

Pubmed ID

23233594

DOI

10.1182/asheducation-2012.1.290

Abstract

A 10-year-old male patient with homozygous sickle cell disease presents for a follow-up clinic visit after a recent hospitalization for a painful vasoocclusive event. His parents mention that in the past year he has had 4 hospitalizations for vasoocclusive events, 2 of which were complicated by the development of acute chest syndrome that resulted in transfer to the intensive care unit. He has missed many school days and may be retained a grade this year. He feels particularly sad about missing the school field trip that occurred during his last hospitalization. He also reports that he is not able to keep up with his friends when participating in physical activities at school. The child's parents are worried that he may be depressed. You as the provider discuss the option of hydroxyurea therapy. His parents ask if hydroxyurea would improve his overall well-being and functioning.

Author List

Darbari DS, Panepinto JA

Author

Julie A. Panepinto MD, MSPH Professor in the Pediatrics department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Acute Disease
Adult
Affect
Anemia, Sickle Cell
Child
Cohort Studies
Critical Care
Cross-Sectional Studies
Hospitalization
Humans
Hydroxyurea
Male
Multicenter Studies as Topic
Quality of Life
Randomized Controlled Trials as Topic
Retrospective Studies
Treatment Outcome
jenkins-FCD Prod-387 b0ced2662056320369de4e5cd5f21c218c03feb3